| Autor: |
Antoni Ribas, Beata Berent-Maoz, Paula J. Kaplan-Lefko, Paula Cabrera, Xiaoyan Wang, Donald B. Kohn, Begonya Comin-Anduix, David Baltimore, Owen N. Witte, Lili Yang, Alexander Nguyen, Celia Adelson, Eric H. Gschweng, Kenneth Cornetta, Daniela Bischof, Beatriz Campo-Fernandez, Roger P. Hollis, Gay M. Crooks, Amelie Montel-Hagen, Christopher S. Seet, Brad Bolon, Jeffrey L. Goodwin, Justin D. Saco, Mignonette H. Macabali, Jia Pang, Marie Desiles S. Komenan, Agustin Vega-Crespo, Nhat A. Truong, Gardenia C. Cheung-Lau, James McCabe, Ameya S. Champhekar, Ruixue Zhang, Salemiz Sandoval, Paige E. Krystofinski, Angel Garcia-Diaz, Giulia Parisi, Cristina Puig-Saus |
| Rok vydání: |
2023 |
| Popis: |
Supplemental Figure 1: Hypothetical model of peripheral blood TCR-transgenic cell repopulation. Supplemental Figure 2: GLP team organizational chart. Supplemental Figure 3. Bone marrow transplant (BMT) optimization studies in HLA-A2/Kb transgenic mice. Supplemental Figure 4. Body weight and hematology assessment at day 5 and 3 months after BMT. Supplemental Figure 5. Spleen and bone marrow cellularity at day 5 and 3 months after BMT. Supplemental Figure 6. Serum chemistry at 3 months after BMT. Supplemental Figure 7. Flow cytometry gating strategy for bone marrow and splenocytes phenotype characterization. Supplemental Figure 8. Survival and hematology 3 months after BMT with Lin- cells transduced with LV-empty, LV-NY-ESO-1 TCR or LV-NY-ESO-1 TCR/sr39TK. Supplemental Figure 9. Differentiation of NYESO TCR/sr39TK-engineered T cells in ATOs (artificial thymic organoids). Supplemental Table 1. Certificate of Analysis of the GMP-comparable LV-NY-ESO-1 TCR/sr39TK (RRL-MSCV-optNYESO-optsr39TK-WPRE, production volume: 20L). Supplemental Table 2. Certificate of Analysis of the Clinical Grade Lentivirus LV-NY-ESO- 1 TCR/sr39TK (RRL-MSCV-optNYESO-optsr39TK-WPRE, production volume 60L). Supplemental Table 3. Certificate of Analysis of the clinical grade RV-NY-ESO-1 TCR (MSGV1-A2aB-1G4A-LY3H10) (Production volume 18L)*. Supplemental Table 4. Certificate of Analysis of the GMP comparable RV-NY-ESO-1 TCR (MSGV1-A2ab-1G4A-Ly3H10, Production volume: 3L). Supplemental Table 5. Co-Administration of NY-ESO-1 TCR Genetically Modified T cells and Hematopoietic Stem Cells (HSCs) in HLA-A2.1/Kb mice. GLP studies cohort distribution. Supplemental Table 6. Cell manufacturing acceptance criteria. Supplemental Table 7. List of protocol-specific organs. Supplemental Table 8. Manufacturing validation runs. Supplemental Table 9. Comparison between fresh and cryopreserved product at 1, 30, 90 and 180# days. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
